Why Is Regeneron Pharmaceuticals Stock Trading Lower Today?
Why Is Regeneron Pharmaceuticals Stock Trading Lower Today?
On Thursday, Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported third-quarter adjusted EPS of $12.46, up 8% year-over-year, beating the consensus of $11.69.
週四，再生元製藥公司（納斯達克股票代碼：REGN）報告第三季度調整後每股收益爲12.46美元，同比增長8%，超過市場預期的11.69美元。
The company reported sales of $3.72 billion, up 11%, beating the consensus of $3.67 billion.
該公司報告的銷售額爲37.2億美元，同比增長11%，超過市場預期的36.7億美元。
"Regeneron had a strong third quarter marked by 11% revenue growth. We continued to deepen the impact of our commercialized medicines this quarter, with ongoing leadership for our retinal franchise, expanded global reach of Libtayo, and notable growth from Dupixent," said Leonard S. Schleifer, Board co-Chair, President and Chief Executive Officer of Regeneron.
「再生元在第三季度取得了強勁增長，營業收入增長11%。在本季度，我們繼續加深了商業化藥品的影響力，在視網膜產品系列方面保持領先地位，擴大了Libtayo的全球影響力，並在Dupixent方面取得了顯著增長，」再生元製藥公司董事會聯席主席、總裁兼首席執行官Leonard S. Schleifer表示。
Also Read: Regeneron Chief Flags Health Risks with Popular Weight-Loss Medications Like Ozempic, Says Company Targets Muscle Preservation For Its Obesity Drugs
此外閱讀：再生元首席警告流行的減肥藥（如奧澤帕）存在健康風險，表示公司旨在保持肌肉並針對其肥胖藥品進行了目標定位。
"Our strong third quarter financial performance was highlighted by double-digit revenue growth and continued investment in our growing pipeline," said Christopher Fenimore, Senior Vice President, Finance and Chief Financial Officer of Regeneron.
「我們強勁的第三季度財務表現突顯出兩位數營業收入增長以及持續對日益增長的項目組合的投資，」再生元製藥公司高級副總裁、財務和首席財務官Christopher Fenimore表示。
Third quarter 2024 U.S. net sales for Eylea HD and Eylea increased 3% versus third quarter 2023 to $1.54 billion, including $392 million from Eylea HD.
2024年第三季度，Eylea HD和Eylea的美國淨銷售額較2023年第三季度增長3%，達到15.4億美元，其中包括來自Eylea HD的39200萬美元。
A lower net selling price adversely impacted the net product sales of EYLEA in the third quarter of 2024.
較低的淨銷售價格對2024年第三季度EYLEA的淨產品銷售額產生了不利影響。
Libtayo global net sales increased by 25% to $289 million.
Libtayo的全球淨銷售額增長了25%，達到28900萬美元。
Sanofi SA (NASDAQ:SNY) collaboration revenue increased from $1.06 billion to $1.26 billion.
賽諾菲安萬特(納斯達克:SNY) 合作營業收入從$10.6億增至$12.6億。
The company said its obesity clinical program is now enrolling.
該公司表示其肥胖症臨床項目現已開始招募。
In its earnings presentation, Regeneron said Phase 2 study to investigate if addition of trevogrumab (anti-myostatin) to Novo Nordisk A/S' (NYSE:NVO) semaglutide with and without garetosmab (antiactivin A) improves the quality of weight loss and/or improves maintenance of weight loss post semaglutide discontinuation.
在其收益報告中，再生元製藥公司表示第2階段研究旨在調查將特魯沃格魯麻布(抗肌肉生成素)添加到Novo Nordisk A/S(紐約交易所:NVO)的塞馬格魯蒂德，帶或不帶加里託麥這一研究是否改善減重質量和/或改善塞馬格魯蒂德停藥後的減重維持情況。
Safety and tolerability data for high-dose trevogrumab in healthy volunteers showed no new safety signals.
健康志願者中高劑量特魯沃格魯麻布的安全性和耐受性數據未顯示出新的安全信號。
The company is on track to complete enrollment by year-end 2024; results for both primary endpoints are expected in 2H25.
該公司將按計劃在2024年底前完成招募工作；預計兩個主要終點的結果將在2025年下半年公佈。
Price Action: REGN stock is down 10.7% at $824.28 at last check Thursday.
股價走勢：REGN股票最新報價下跌10.7%，爲每股$824.28，截至週四最後交易。
Photo via Shutterstock
圖片來自shutterstock。
- Cigna's Q3 Profit Beats Street On Strong Demand For Pharmacy Benefit Management's Specialty Drugs, New Clients
- Cigna第三季度利潤超出預期，受益於強勁需求的藥房福利管理特殊藥品和新客戶
譯文內容由第三人軟體翻譯。
